521 related articles for article (PubMed ID: 27673290)
21. Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation.
Blimark C; Veskovski L; Westin J; Rödjer S; Brune M; Hjorth M; Holmberg E; Andersson PO; Mellqvist UH
Eur J Haematol; 2011 Aug; 87(2):117-22. PubMed ID: 21535157
[TBL] [Abstract][Full Text] [Related]
22. The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantation.
Fleming S; Harrison SJ; Blombery P; Joyce T; Stokes K; Seymour JF; Prince HM; Ritchie D
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):291-6. PubMed ID: 24629850
[TBL] [Abstract][Full Text] [Related]
23. High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma.
Sivaraj D; Bacon W; Long GD; Rizzieri DA; Horwitz ME; Sullivan KM; Kang Y; Li Z; Chao NJ; Gasparetto C
Bone Marrow Transplant; 2018 Jan; 53(1):34-38. PubMed ID: 29084203
[TBL] [Abstract][Full Text] [Related]
24. XRCC1-mediated DNA repair is associated with progression-free survival of multiple myeloma patients after autologous stem cell transplant.
Persaud AK; Li J; Johnson JA; Seligson N; Sborov DW; Duah E; Cho YK; Wang D; Phelps MA; Hofmeister CC; Poi MJ
Mol Carcinog; 2019 Dec; 58(12):2327-2339. PubMed ID: 31544312
[TBL] [Abstract][Full Text] [Related]
25. [Updated treatment strategy for transplant-eligible multiple myeloma: current status and future perspectives].
Tsukada N
Rinsho Ketsueki; 2023; 64(9):1066-1073. PubMed ID: 37899184
[TBL] [Abstract][Full Text] [Related]
26. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs.
Martino M; Postorino M; Gallo GA; Messina G; Neri S; Piro E; Gentile M; Moscato T; Monteleone R; Fedele R; Mazzone C; Console G; Penna G; Alati C; Vincelli ID; Irrera G; Musolino C; Ronco F; Molica S; Morabito F
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):148-54. PubMed ID: 24417912
[TBL] [Abstract][Full Text] [Related]
27. Treatment for patients with newly diagnosed multiple myeloma in 2015.
Mateos MV; Ocio EM; Paiva B; Rosiñol L; Martínez-López J; Bladé J; Lahuerta JJ; García-Sanz R; San Miguel JF
Blood Rev; 2015 Nov; 29(6):387-403. PubMed ID: 26094881
[TBL] [Abstract][Full Text] [Related]
28. High-dose melphalan +/- total body irradiation and autologous hematopoietic stem cell rescue for adult patients with Ewing's sarcoma or peripheral neuroectodermal tumor.
Stewart DA; Gyonyor E; Paterson AH; Arthur K; Temple W; Schachar NS; Klassen J; Brown C; Russell JA
Bone Marrow Transplant; 1996 Aug; 18(2):315-8. PubMed ID: 8864440
[TBL] [Abstract][Full Text] [Related]
29. High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma.
Huijgens PC; Dekker-Van Roessel HM; Jonkhoff AR; Admiraal GC; Zweegman S; Schuurhuis GJ; Ossenkoppele GJ
Bone Marrow Transplant; 2001 May; 27(9):925-31. PubMed ID: 11436102
[TBL] [Abstract][Full Text] [Related]
30. High dose therapy followed by autologous peripheral blood stem cell transplantation as a first line treatment for multiple myeloma: a Korean Multicenter Study.
Bang SM; Cho EK; Suh C; Yoon SS; Seong CM; Cho KS; Kang YG; Park S; Ahn MJ; Park YS; Oh D; Kim HC; Jung CW; Kim S; Lee JH
J Korean Med Sci; 2003 Oct; 18(5):673-8. PubMed ID: 14555819
[TBL] [Abstract][Full Text] [Related]
31. Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma.
Hashmi H; Atrash S; Jain J; Khasawneh G; Mohan M; Mahmoudjafari Z; Cui W; McGuirk J; Shune L; Ahmed N; Abdallah AO
Transplant Cell Ther; 2023 Apr; 29(4):262.e1-262.e6. PubMed ID: 36682468
[TBL] [Abstract][Full Text] [Related]
32. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
[TBL] [Abstract][Full Text] [Related]
33. Recommend upfront consolidation with high-dose melphalan and autologous stem cell support.
Shah GL; Giralt SA
Semin Oncol; 2016 Dec; 43(6):707-708. PubMed ID: 28061992
[TBL] [Abstract][Full Text] [Related]
34. Multiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy.
Rocchi S; Zannetti BA; Marconi G; Lanza F
Cells; 2024 May; 13(10):. PubMed ID: 38786075
[TBL] [Abstract][Full Text] [Related]
35. Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?
Caraux A; Vincent L; Bouhya S; Quittet P; Moreaux J; Requirand G; Veyrune JL; Olivier G; Cartron G; Rossi JF; Klein B
Oncotarget; 2012 Nov; 3(11):1335-47. PubMed ID: 23154454
[TBL] [Abstract][Full Text] [Related]
36. Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma.
Straka C; Salwender H; Knop S; Vogel M; Müller J; Metzner B; Langer C; Sayer H; Jung W; Dürk HA; Bassermann F; Gramatzki M; Rösler W; Wolf HH; Brugger W; Engelhardt M; Fischer T; Liebisch P; Einsele H
Eur J Haematol; 2021 Nov; 107(5):529-542. PubMed ID: 34270825
[TBL] [Abstract][Full Text] [Related]
37. The role of autologous stem-cell transplantation in multiple myeloma in 2021.
Mina R; Gay F
Curr Opin Oncol; 2021 Nov; 33(6):642-647. PubMed ID: 34419954
[TBL] [Abstract][Full Text] [Related]
38. Autologous transplantation and maintenance therapy in multiple myeloma.
Palumbo A; Cavallo F; Gay F; Di Raimondo F; Ben Yehuda D; Petrucci MT; Pezzatti S; Caravita T; Cerrato C; Ribakovsky E; Genuardi M; Cafro A; Marcatti M; Catalano L; Offidani M; Carella AM; Zamagni E; Patriarca F; Musto P; Evangelista A; Ciccone G; Omedé P; Crippa C; Corradini P; Nagler A; Boccadoro M; Cavo M
N Engl J Med; 2014 Sep; 371(10):895-905. PubMed ID: 25184862
[TBL] [Abstract][Full Text] [Related]
39. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.
Musso M; Messina G; Marcacci G; Crescimanno A; Console G; Donnarumma D; Scalone R; Pinto A; Martino M
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1932-8. PubMed ID: 26099830
[TBL] [Abstract][Full Text] [Related]
40. Melphalan-based autologous transplant in octogenarian multiple myeloma patients.
Saini NY; Patel R; Varma A; Bashir Q; Delgado R; Rondon G; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Weber DM; Thomas SK; Lee HC; Manasanch EE; Patel KK; Orlowski RZ; Champlin RE; Qazilbash MH
Am J Hematol; 2019 Jan; 94(1):E2-E5. PubMed ID: 30300461
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
